Alps Advisors Inc. bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,544 shares of the medical research company’s stock, valued at approximately $2,818,000.
Several other institutional investors and hedge funds have also made changes to their positions in TMO. FNY Investment Advisers LLC purchased a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $103,000. Horrell Capital Management Inc. purchased a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $104,000. Edge Wealth Management LLC grew its position in shares of Thermo Fisher Scientific by 8,077.8% during the second quarter. Edge Wealth Management LLC now owns 736 shares of the medical research company’s stock worth $152,000 after acquiring an additional 727 shares during the last quarter. Atlantic Trust LLC purchased a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $154,000. Finally, First Command Bank purchased a new position in shares of Thermo Fisher Scientific during the second quarter worth approximately $182,000. Institutional investors and hedge funds own 85.47% of the company’s stock.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 125,520 shares of the firm’s stock in a transaction on Monday, October 1st. The stock was sold at an average price of $247.50, for a total value of $31,066,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Tyler Jacks sold 4,772 shares of the firm’s stock in a transaction on Monday, November 19th. The shares were sold at an average price of $239.75, for a total value of $1,144,087.00. The disclosure for this sale can be found here. 0.49% of the stock is currently owned by company insiders.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 24th. The medical research company reported $2.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.55 by $0.07. Thermo Fisher Scientific had a return on equity of 16.49% and a net margin of 10.75%. The firm had revenue of $5.92 billion during the quarter, compared to the consensus estimate of $5.70 billion. During the same period last year, the company earned $2.31 earnings per share. The company’s revenue for the quarter was up 15.7% on a year-over-year basis. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 11.04 earnings per share for the current fiscal year.
Thermo Fisher Scientific announced that its board has approved a share repurchase plan on Friday, September 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2.1% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s board believes its shares are undervalued.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, January 15th. Shareholders of record on Monday, December 17th will be issued a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend is Friday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 7.17%.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $274.00 target price on the stock in a research report on Monday, October 1st. Barclays raised their target price on shares of Thermo Fisher Scientific from $250.00 to $275.00 and gave the stock an “overweight” rating in a research report on Monday, September 24th. Goldman Sachs Group lowered shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research report on Monday, September 17th. Citigroup increased their price target on Thermo Fisher Scientific from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, October 10th. Finally, Morgan Stanley increased their price target on Thermo Fisher Scientific from $242.00 to $254.00 and gave the stock an “overweight” rating in a report on Wednesday, October 10th. Two equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $263.55.
WARNING: This piece was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://baseballnewssource.com/2018/11/21/11544-shares-in-thermo-fisher-scientific-inc-tmo-purchased-by-alps-advisors-inc/2901439.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
See Also: How Short Selling Works
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.